Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.

Hen N, Shekh-Ahmad T, Yagen B, McDonough JH, Finnell RH, Wlodarczyk B, Bialer M.

J Med Chem. 2013 Aug 22;56(16):6467-77. doi: 10.1021/jm4007565. Epub 2013 Aug 7.

PMID:
23879329
2.

The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.

Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M.

Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13. Review.

PMID:
25979572
3.

Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential.

Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, Bialer M.

Epilepsia. 2014 Feb;55(2):353-61. doi: 10.1111/epi.12480. Epub 2013 Dec 6.

4.

A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.

White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, McDonough JH, Stables JP, Kaufmann D, Yagen B, Bialer M.

Epilepsia. 2012 Jan;53(1):134-46. doi: 10.1111/j.1528-1167.2011.03338.x. Epub 2011 Dec 9. Erratum in: Epilepsia. 2012 Feb;53(2):397.

5.

sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats.

Bar-Klein G, Swissa E, Kamintsky L, Shekh-Ahmad T, Saar-Ashkenazy R, Hubary Y, Shrot S, Stetlander L, Eisenkraft A, Friedman A, Bialer M.

Epilepsia. 2014 Dec;55(12):1953-8. doi: 10.1111/epi.12838. Epub 2014 Nov 6.

6.

Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid.

Kaufmann D, Yagen B, Minert A, Wlodarczyk B, Finnell RH, Schurig V, Devor M, Bialer M.

Neuropharmacology. 2010 Jun;58(8):1228-36. doi: 10.1016/j.neuropharm.2010.03.004. Epub 2010 Mar 15.

PMID:
20230843
7.

Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid.

Mawasi H, Shekh-Ahmad T, Finnell RH, Wlodarczyk BJ, Bialer M.

Epilepsy Behav. 2015 May;46:72-8. doi: 10.1016/j.yebeh.2015.02.040. Epub 2015 Apr 8.

PMID:
25863940
8.

Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative.

Shimshoni JA, Yagen B, Wlodarczyk B, Finnell RH, Schurig V, Bialer M.

Epilepsia. 2010 Mar;51(3):323-32. doi: 10.1111/j.1528-1167.2009.02241.x. Epub 2009 Aug 8.

9.

Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid.

Shekh-Ahmad T, Mawasi H, McDonough JH, Finnell RH, Wlodarczyk BJ, Yavin E, Bialer M.

Epilepsia. 2014 Dec;55(12):1944-52. doi: 10.1111/epi.12857. Epub 2014 Nov 29.

10.

Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus.

Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M.

Epilepsia. 2013 Sep;54 Suppl 6:99-102. doi: 10.1111/epi.12290.

11.

Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus.

Mawasi H, Bibi D, Shekh-Ahmad T, Shaul C, Blotnik S, Bialer M.

Mol Pharm. 2016 Jul 5;13(7):2492-6. doi: 10.1021/acs.molpharmaceut.6b00221. Epub 2016 Jun 2.

PMID:
27218460
12.

Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.

Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B, Bialer M.

Pharm Res. 2003 Aug;20(8):1293-301.

PMID:
12948028
13.

A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus.

Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, Ricks K, Roach B, Nelson C, Dudek FE.

Neuroscience. 2013 Feb 12;231:145-56. doi: 10.1016/j.neuroscience.2012.11.005. Epub 2012 Nov 14.

PMID:
23159312
14.

Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.

Spiegelstein O, Yagen B, Levy RH, Finnell RH, Bennett GD, Roeder M, Schurig V, Bialer M.

Pharm Res. 1999 Oct;16(10):1582-8.

PMID:
10554101
15.
16.

Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.

Okada A, Noyori H, Yagen B, Shimshoni JA, Bialer M, Fujiwara M.

Birth Defects Res B Dev Reprod Toxicol. 2009 Oct;86(5):394-401. doi: 10.1002/bdrb.20209.

PMID:
19830722
17.

Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats.

MareŇ° P, Kubov√° H, Hen N, Yagen B, Bialer M.

Epilepsy Res. 2013 Sep;106(1-2):64-73. doi: 10.1016/j.eplepsyres.2013.06.001. Epub 2013 Jun 28.

PMID:
23815889
18.

Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.

Bialer M, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, Herzig Y, Shirvan M.

Biopharm Drug Dispos. 1996 Oct;17(7):565-75.

PMID:
8894115
19.

Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.

Pessah N, Kaufmann D, Yagen B, Hen N, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsia. 2010 Oct;51(10):1944-53. doi: 10.1111/j.1528-1167.2010.02684.x.

20.

Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.

Shimshoni JA, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsia. 2008 Jul;49(7):1202-12. doi: 10.1111/j.1528-1167.2008.01624.x.

Supplemental Content

Support Center